Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Treatment of prolymphocytic leukemia

Journal Article · · Cancer (Philadelphia); (United States)
Prolymphocytic leukemia is characterized by marked splenomegaly, distinctive cellular morphologic characteristics, and a poor clinical course. Five patients with typical PL were treated systematically with vincristine/prednisone, chlorambucil/prednisone, splenic irradiation, splenectomy, and other chemotherapy regimens. No patient responded to vincristine/prednisone. Two patients responded to chlorambucil/prednisone, and four patients had brief responses to splenic irradiation. Two patients underwent splenectomy, one of whom had a prolonged clinical remission. There were no complete remissions. No other chemotherapy combinations were of value. The median survival was 33 months. Recommendations are made to use chlorambucil/prednisone or splenic irradiation as initial treatment. Splenectomy should be considered in patients refractory to these modalities. The course of PL may be more protracted than originally reported.
Research Organization:
Department of Medicine, Cornell University Medical College, New York, New York
OSTI ID:
6581569
Journal Information:
Cancer (Philadelphia); (United States), Journal Name: Cancer (Philadelphia); (United States) Vol. 50:9; ISSN CANCA
Country of Publication:
United States
Language:
English